LLY Eli Lilly and Company
Company Analysis
Latest News
Indiana Sues Eli Lilly Over Alleged Insulin Price-Fixing Scheme
Indiana Attorney General Todd Rokita filed a new lawsuit against Eli Lilly on December 31, 2025, alleging an insulin price-fixing scheme. The lawsuit claims...
🔴 LLY is trading 3% down today as rival Novo Nordisk begins selling obesity pill in U.S.
LLY is trading at $1045.85 (-3.19%) following reports of a 4% drop linked to competitor Novo Nordisk launching its obesity pill in the U.S., intensifying...
Eli Lilly Anticipates Key Readouts for Obesity and Alzheimer's Drugs in H1 2026
Eli Lilly faces a significant period in the first half of 2026, driven by two major clinical milestones. Both events are scheduled for March. The first...
Eli Lilly Sees Certain Fraud Claims Trimmed in Insulin-Pricing Lawsuit
The U.S. District Court for the District of New Jersey dismissed certain civil fraud claims against Eli Lilly & Co. and other drugmakers. The claims related to...
Eli Lilly and Boehringer Ingelheim to Cut Jardiance Price by Over 40%
Eli Lilly and partner Boehringer Ingelheim will cut the U.S. list price of the diabetes drug Jardiance and related treatments. The reduction exceeds 40%. This...
Eli Lilly and Partner Vanda Pharmaceuticals Gain FDA Approval for Novel Motion Sickness Drug
Eli Lilly and Vanda Pharmaceuticals secured FDA approval for Nereus (tradipitant). The drug is indicated for the prevention of vomiting induced by...
Eli Lilly Slashes Mounjaro Prices in China Amidst Growing Competition
Eli Lilly and Company implemented a significant price reduction for its popular weight-loss drug, Mounjaro, in the Chinese market. Reports citing Chinese drug...
Eli Lilly Faces Enhanced Oral Weight-Loss Competition as Novo Nordisk Secures First FDA Approval
Novo Nordisk secured U.S. FDA approval for its oral Wegovy on December 23, positioning it as the first oral weight-loss GLP-1 drug on the market. This...
Eli Lilly's Potential Abivax Takeover Speculation Intensifies
Speculation regarding a potential takeover of French biotech Abivax by Eli Lilly intensified on December 22, 2025. Fresh reports allege that Eli Lilly...
🟢 LLY is trading 3% up today on positive Phase 3 data for oral drug orforglipron
LLY is trading at +3.06% now at $1073.65 following the announcement of positive Phase 3 trial results for its oral weight-loss drug, orforglipron. * The...
🟢 LLY is trading 2.6% up today after bullish Bank of America obesity outlook
LLY is trading at 2.6% up now at $1054.43 after receiving fresh bullish analyst commentary regarding its highly valued obesity franchise. Bank of America...
🟢 LLY is trading 2.6% up today
LLY is trading at +2.6% now at $1054.62, bucking broader market weakness where the S&P 500 is down 0.09% and NASDAQ is down 0.39%. BofA Securities lowered...
🟢 LLY is trading 3.2% up today
LLY is trading at $1060.52 (+3.21%), significantly outperforming a modestly lower market, driven by continuing momentum in its obesity drug portfolio...
🟢 LLY is trading 3.2% up today
LLY is trading at $1060.51 (+3.21%), significantly outperforming the broader market weakness and tech pressures. The gain occurs amid a slightly lower...
Eli Lilly's Retatrutide Phase 3 Results Exceed Expectations, Showing Significant Weight Loss and Pain Relief
Eli Lilly announced highly positive topline results from the Phase 3 TRIUMPH-4 trial for retatrutide, its next-generation obesity drug. The triple agonist...
Eli Lilly's Stock Declines for Ninth Consecutive Day Amid Investor Scrutiny
Eli Lilly stock fell for a ninth consecutive day on December 9, 2025, raising investor concerns despite a series of positive strategic announcements. This...
Eli Lilly Invests $6 Billion in New Alabama Manufacturing Facility to Boost Production of Weight-Loss and Diabetes Drugs
Eli Lilly and Company selected Huntsville, Alabama, for a new $6 billion manufacturing plant. Lilly will dedicate the facility to producing Active...
LLY's Dow Exclusion Debated Amid Trillion-Dollar Valuation
Eli Lilly & Co. remains conspicuously absent from the Dow 30, despite briefly topping a $1 trillion market cap on November 21, 2025, driven by blockbuster...
Eli Lilly Gains Key Access to Chinese Market with Inclusion in First Private Insurance Drug Catalog
Eli Lilly's innovative drugs have been included in China's inaugural private insurance catalog, a move set to enhance sales prospects for advanced, high-cost...
Eli Lilly Gains Expanded FDA Approval for Cancer Drug Jaypirca
Eli Lilly and Company announced it has received expanded approval from the U.S. Food and Drug Administration (FDA) for its cancer treatment, Jaypirca. The drug...